Shosukabu.com Acquires Majority Stake in Biotech Leader Kawano Mericlone

Overview Shosukabu.com has announced the acquisition of a majority stake in Kawano Mericlone, a Japanese leader in advanced plant biotechnology and tissue culture. With this acquisition, Kawano Mericlone has become a subsidiary of Shosukabu.com.

By integrating Shosukabu.com's expertise in building corporate governance structures and optimizing capital efficiency with Kawano Mericlone's world-class mericlone (tissue culture) technology, the two companies aim to build a new growth model for Japan's agricultural sector.

Background and Objectives of the Acquisition Shosukabu.com identifies the agricultural sector—a traditional Japanese industry with massive untapped potential for growth through technology and structural reform—as a core area for future growth investment.

Kawano Mericlone is a pioneer in the biotech industry, globally recognized for its massive propagation technology for Cymbidiums and other high-value-added plants. Their advanced sterile culture technology and expertise in maintaining genetic stability for mass production hold significant market value for future food security and the advancement of agri-tech.

Through management and capital support, Shosukabu.com aims to achieve a breakthrough in Kawano Mericlone's long-term corporate value.

Future Outlook Shosukabu.com plans to conduct a site visit in June 2026 to the Netherlands, a global hub for advanced facility horticulture and smart agriculture.

By combining the Netherlands' advanced environmental control technologies, automated systems, and efficient supply chain knowledge with Kawano Mericlone's biotech expertise, the company intends to establish a next-generation smart agricultural model in Japan. Furthermore, it seeks to create powerful synergies to expand high-quality Japanese agricultural products and technologies into the international market.